Scinai Immunotherapeutics (SCNI) Cash from Financing Activities (2019 - 2026)
Scinai Immunotherapeutics (SCNI) reported Cash from Financing Activities of $11000.0 for Q1 2026, down 89.42% on a YoY basis from $104000.0 in Q1 2025, and down 99.26% sequentially from $1.5 million in Q2 2025.
Scinai Immunotherapeutics (SCNI) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Scinai Immunotherapeutics (SCNI) has 7 years of Cash from Financing Activities data on file, last reported at $11000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 89.42% year-over-year to $11000.0; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (up 69.11% YoY), and the FY2025 full-year result was $5.8 million, up 67.68% from the prior year.
- Cash from Financing Activities declined to $11000.0 in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $2.0 million in Q4 2024 to a low of -$468000.0 in Q2 2022.
- A 4-year average of $570625.0 and a median of $58000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 12208.33% in 2025, while the deepest fall reached 92.68% in 2025.
- Tracing SCNI's Cash from Financing Activities over 4 years: stood at -$468000.0 in 2022, then surged by 527.35% to $2.0 million in 2024, then dropped by 26.15% to $1.5 million in 2025, then slumped by 99.26% to $11000.0 in 2026.
- Business Quant data shows SCNI's Cash from Financing Activities at $11000.0 in Q1 2026, $1.5 million in Q2 2025, and $104000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Scinai Immunotherapeutics | 352,860.00 | -3.11 Bn | -1.12 Mn | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Jun 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 104,000.00 |
| Mar 31, 2025 | 104,000.00 |
| Dec 31, 2024 | 2.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Jun 30, 2022 | -468,000.00 |
| Jun 30, 2022 | -468,000.00 |
| Dec 31, 2021 | 8.88 Mn |
| Dec 31, 2021 | 8.88 Mn |
| Sep 30, 2021 | -988,000.00 |
| Sep 30, 2021 | -988,000.00 |